Clinical Outcome and Prognostic Factors of Intensity-Modulated Radiotherapy for T4 Stage Nasopharyngeal Carcinoma

被引:13
作者
Luo, Yangkun [1 ]
Gao, Yang [2 ]
Yang, Guangquan [1 ]
Lang, Jinyi [1 ]
机构
[1] Sichuan Canc Hosp, Dept Radiat Oncol, Chengdu 610041, Peoples R China
[2] Zigong 4 Peoples Hosp Sichuan Prov, Dept Radiat Oncol, Zigong 643000, Peoples R China
关键词
CONCURRENT CISPLATIN-RADIOTHERAPY; RANDOMIZED PHASE-II; RADIATION-THERAPY; INDUCTION CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; SURVIVAL; CHEMORADIOTHERAPY; UPDATE; CANCER; TRIAL;
D O I
10.1155/2016/4398498
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective. To analyze the clinical outcomes and prognostic factors of intensity-modulated radiotherapy (IMRT) for T4 stage nasopharyngeal carcinoma (NPC). Methods. Between March 2005 and March 2010, 110 patients with T4 stage NPC without distant metastases were treated. All patients received IMRT. Induction and/or concurrent chemotherapy were given. 47 (42.7%) patients received IMRT replanning. Results. The 5-year local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS) rates were 90.1%, 97.0%, 67.5%, 63.9%, and 64.5%, respectively. Eleven patients experienced local-regional failure and total distant metastasis occurred in 34 patients. 45 patients died and 26 patients died of distant metastasis alone. The 5-year LRFS rates were 97.7% and 83.8% for the patients that received and did not receive IMRT replanning, respectively (P = 0.023). Metastasis to the retropharyngeal lymph nodes (RLN) was associated with inferior 5-year OS rate (61.0% versus 91.7%, P = 0.034). The gross tumor volume of the right/left lymph nodes (GTVln) was an independent prognostic factor for DMFS (P = 0.006) and PFS (P = 0.018). GTVln was with marginal significance as the prognostic factor for OS (P = 0.050). Conclusion. IMRT provides excellent local-regional control for T4 stage NPC. Benefit of IMRT replanning may be associated with improvement in local control. Incorporating GTVln into the N staging system may provide better prognostic information.
引用
收藏
页数:9
相关论文
共 35 条
[1]  
Allisy A., 1993, ICRU REPORT 50 PRESC
[2]  
[Anonymous], 50 ICRU S
[3]   Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer [J].
Bae, Woo Kyun ;
Hwang, Jun Eul ;
Shim, Hyun Jeong ;
Cho, Sang Hee ;
Lee, Joon Kyoo ;
Lim, Sang-Chul ;
Chung, Woong-Ki ;
Chung, Ik-Joo .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (03) :589-595
[4]   Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis [J].
Blanchard, Pierre ;
Lee, Anne ;
Marguet, Sophie ;
Leclercq, Julie ;
Ng, Wai Tong ;
Ma, Jun ;
Chan, Anthony T. C. ;
Huang, Pei-Yu ;
Benhamou, Ellen ;
Zhu, Guopei ;
Chua, Daniel T. T. ;
Chen, Yong ;
Mai, Hai-Qiang ;
Kwong, Dora L. W. ;
Cheah, Shie Lee ;
Moon, James ;
Tung, Yuk ;
Chi, Kwan-Hwa ;
Fountzilas, George ;
Zhang, Li ;
Hui, Edwin Pun ;
Lu, Tai-Xiang ;
Bourhis, Jean ;
Pignon, Jean Pierre .
LANCET ONCOLOGY, 2015, 16 (06) :645-655
[5]   Update report of T4 classification nasopharyngeal carcinoma after intensity-modulated radiotherapy: An analysis of survival and treatment toxicities [J].
Cao, Cai-neng ;
Luo, Jin-wei ;
Gao, Li ;
Yi, Jun-lin ;
Huang, Xiao-dong ;
Wang, Kai ;
Zhang, Shi-ping ;
Qu, Yuan ;
Li, Su-yan ;
Xiao, Jian-ping ;
Zhang, Zhong ;
Xu, Guo-zhen .
ORAL ONCOLOGY, 2015, 51 (02) :190-194
[6]   Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma [J].
Chan, ATC ;
Leung, SF ;
Ngan, RKC ;
Teo, PML ;
Lau, WH ;
Kwan, WH ;
Hui, EP ;
Yiu, HY ;
Yeo, W ;
Cheung, FY ;
Yu, KH ;
Chiu, KW ;
Chan, DT ;
Mok, TSK ;
Yau, S ;
Yuen, KT ;
Mo, FKF ;
Lai, MMP ;
Ma, BBY ;
Kam, MKM ;
Leung, TWT ;
Johnson, PJ ;
Choi, PHK ;
Zee, BCY .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (07) :536-539
[7]   Nasopharyngeal carcinoma [J].
Chan, ATC ;
Teo, PML ;
Johnson, PJ .
ANNALS OF ONCOLOGY, 2002, 13 (07) :1007-1015
[8]   Clinical outcomes among patients with head and neck cancer treated by intensity-modulated radiotherapy with and without adaptive replanning [J].
Chen, Allen M. ;
Daly, Megan E. ;
Cui, Jing ;
Mathai, Mathew ;
Benedict, Stanley ;
Purdy, James A. .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2014, 36 (11) :1541-1546
[9]   Prognostic Value of Subclassification Using MRI in the T4 Classification Nasopharyngeal Carcinoma Intensity-Modulated Radiotherapy Treatment [J].
Chen, Lei ;
Liu, Li-Zhi ;
Chen, Mo ;
Li, Wen-Fei ;
Yin, Wen-Jing ;
Lin, Ai-Hua ;
Sun, Ying ;
Li, Li ;
Ma, Jun .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (01) :196-202
[10]   Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial [J].
Chen, Lei ;
Hu, Chao-Su ;
Chen, Xiao-Zhong ;
Hu, Guo-Qing ;
Cheng, Zhi-Bin ;
Sun, Yan ;
Li, Wei-Xiong ;
Chen, Yuan-Yuan ;
Xie, Fang-Yun ;
Liang, Shao-Bo ;
Chen, Yong ;
Xu, Ting-Ting ;
Li, Bin ;
Long, Guo-Xian ;
Wang, Si-Yang ;
Zheng, Bao-Min ;
Guo, Ying ;
Sun, Ying ;
Mao, Yan-Ping ;
Tang, Ling-Long ;
Chen, Yu-Ming ;
Liu, Meng-Zhong ;
Ma, Jun .
LANCET ONCOLOGY, 2012, 13 (02) :163-171